| Bioactivity | DMA is a fluorescent compound (λex=340 nm, λem=478 nm). | ||||||||||||
| Target | IC50: 3.4 μM (HeLa cell), 5.3 μM (MCF7 cell) | ||||||||||||
| Invitro | The newly synthesized bisbenzimidazole derivatives DMA (6c) is evaluated for their cytotoxicity against human tumor cell lines, which are cervix carcinoma cell line (HeLa), breast carcinoma cell line (MCF7) and brain glioma cell line (U87) in comparison to Hoechst. In case of MCF7, the IC50 is observed at 5.3 μM for DMA. The IC50 determined in the case of HeLa is 3.4 μM for DMA[1]. | ||||||||||||
| Name | DMA | ||||||||||||
| CAS | 188860-26-6 | ||||||||||||
| Formula | C27H28N6O2 | ||||||||||||
| Molar Mass | 468.55 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Singh M, et al. Synthesis and biological activity of novel inhibitors of topoisomerase I: 2-aryl-substituted 2-bis-1H-benzimidazoles. Eur J Med Chem. 2011 Feb;46(2):659-69. |